Expression of Ep-CAM in intestinal metaplasia, gastric epithelial dysplasia and gastric adenocarcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue 7, 2005, Pages 1039-1045

  Joo, Mee ^a   Kim, Hanseong ^a   Kim, Min Kyung ^a   Yu, Hang Jong ^b   Kim, Jin Pok ^b  

^a Inje University   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

Cell adhesion molecule; Ep CAM; Epithelial dysplasia; Gastric carcinoma; Intestinal metaplasia

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE;

ADULT; ARTICLE; CANCER GRADING; CHRONIC GASTRITIS; CONTROLLED STUDY; DYSPLASIA; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; STOMACH ADENOCARCINOMA; STOMACH BIOPSY; STOMACH EPITHELIUM; STOMACH MUCOSA;

ADENOCARCINOMA; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; FEMALE; GASTRIC MUCOSA; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINES; MALE; METAPLASIA; MIDDLE AGED; NEOPLASM STAGING; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 21844444327     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.03842.x     Document Type: Article

References (25)

1. Litvinov SV, Balzar M, Winter MJ et al. Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J. Cell Biol. 1997; 139: 1337-48.
2. Balzar M, Winter MJ, de Boer CJ et al. The biology of the 17-1A antigen (Ep-CAM). J. Mol. Med. 1999; 77: 699-712.
3. Winter MJ, Nagtegaal ID, van Krieken JH et al. The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am. J. Pathol. 2003; 163: 2139-48.
4. Went PT, Lugli A, Meier S et al. Frequent EpCAM protein expression in human carcinomas. Hum. Pathol. 2004; 35: 122-8.
5. Mellstedt H, Fagerberg J, Frodin JE et al. Ga733/EpCAM as a target for passive and active specific immunotherapy in patients with colorectal carcinoma. Ann. N. Y. Acad. Sci. 2000; 910: 254-61; discussion 261-2.
6. Spizzo G, Obrist P, Ensinger C et al. Prognostic significance of Ep-CAM and Her-2/neu overexpression in invasive breast cancer. Int. J. Cancer 2002; 98: 883-8.
7. Kim JH, Herlyn D, Wong KK et al. Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin. Cancer Res. 2003; 9: 4782-91.
8. Watanabe R, Johzaki H, Iwasaki H et al. A new tumor-associated antigen defined by a monoclonal antibody directed to gastric adenocarcinoma. Cancer 1993; 71: 2439-47.
9. Songun I, van de Velde CJ, Hermans J et al. Expression of oncoproteins and the amount of eosinophilic and lymphocytic infiltrates can be used as prognostic factors in gastric cancer. Dutch Gastric Cancer Group (DGCG). Br. J. Cancer 1996; 74: 1783-8.
10. Filipe MI, Munoz N, Matko I et al. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int. J. Cancer 1994; 57: 324-9.
11. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process: First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992; 52: 6735-40.
12. Walker MM. Is intestinal metaplasia of the stomach reversible? Gut 2003; 52: 1-4.
13. Reis CA, David L, Correa P et al. Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression. Cancer Res. 1999; 59: 1003-7.
14. Almeida R, Silva E, Santos-Silva F et al. Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas. J. Pathol. 2003; 199: 36-40.
15. Grötzinger C, Kneifel J, Patschan D et al. Li-cadherin: a marker of gastric metaplasia and neoplasia. Gut 2001; 49: 73-81.
16. Chu PG, Jiang Z, Weiss LM. Hepatocyte antigen as a marker of intestinal metaplasia. Am. J. Surg. Pathol. 2003; 27: 952-9.
17. Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med. 1994; 331: 1259-64.
18. Dixon MF, Genta RM, Yardley JH et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am. J. Surg. Pathol. 1996; 20: 1161-81.
19. Shiao YH, Rugge M, Correa P et al. p53 alteration in gastric precancerous lesions. Am. J. Pathol. 1994; 144: 511-17.
20. Sung JJ, Leung WK, Go MY et al. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am. J. Pathol. 2000; 157: 729-35.
21. Leung WK, Kim JJ, Kim JG et al. Microsatellite instability in gastric intestinal metaplasia in patients with and without gastric cancer. Am. J. Pathol. 2000; 156: 537-43.
22. Kang GH, Shim YH, Jung HY et al. CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res. 2001; 61: 2847-51.
23. Chan AO, Lam SK, Wong BC et al. Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer. Gut 2003; 52: 502-6.
24. Poczatek RB, Myers RB, Manne U et al. Ep-CAM levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J. Urol. 1999; 162: 1462-6.
25. Litvinov SV, van Driel W, van Rhijn CM et al. Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation. Am. J. Pathol. 1996; 148: 865-75.